Skip to main content

Advertisement

Log in

Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Biological therapy for ankylosing spondylitis (AS) has led to improved disease control beyond that of conventional treatments. International recommendations encourage clinicians prescribing biological treatments to register patients in national registers to collect information on outcome and toxicity. Patients with AS (n = 229) from the Register of Biological Treatment in Finland (ROB-FIN) with severe disease of long duration were followed-up for up to 24 months. Due to an active disease, one or more concomitant disease-modifying antirheumatic drugs (DMARDs) were used by 86% at commencement of biological therapy. This add-on strategy with infliximab led to a rapid pain relief and improvement of patient’s and physician’s global assessments, C-reactive protein/erythrocyte sedimentation rate, and swollen and tender joint counts within 6 weeks. Concomitant use of NSAID and oral corticosteroid was reduced. Corresponding results were documented at 3 months with etanercept, which was more recently approved for the treatment of spondyloarthropathies. Seventy-nine percent of the patients were ASAS 20 responders. A subgroup of AS patients with only axial involvement (n = 46) responded correspondingly. The first biological drug was discontinued in only 7% due to lack of efficacy and in 6% due to adverse events. Anti-TNF agents, often used in combination with DMARDs, appeared to have persistent effectiveness and limited toxicity in a real-life clinical setting in a cohort of Finnish AS patients with severe disease and long disease duration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. http://www.kaypahoito.fi, in Finnish

References

  1. Braun J, Sieper J (2002) Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches. Arthritis Res 4:307–321

    Article  PubMed  CAS  Google Scholar 

  2. Boulos P, Dougados M, MacLeod SM et al (2005) Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 65:2111–2127

    Article  PubMed  CAS  Google Scholar 

  3. Zochling J, Braun J (2005) Management and treatment of ankylosing spondylitis. Curr Opin Rheumatol 17:418–425

    Article  PubMed  CAS  Google Scholar 

  4. Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193

    Article  PubMed  CAS  Google Scholar 

  5. Davis JC Jr, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230–3236

    Article  PubMed  CAS  Google Scholar 

  6. Calin A, Dijkmans BAC, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600

    Article  PubMed  CAS  Google Scholar 

  7. Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568–1575

    Article  PubMed  CAS  Google Scholar 

  8. van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591

    Article  PubMed  Google Scholar 

  9. Braun J, Pham T, Sieper J et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824

    Article  PubMed  CAS  Google Scholar 

  10. Braun J, Davis J, Dougados M et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316–320

    Article  PubMed  CAS  Google Scholar 

  11. Konttinen L, Honkanen V, Uotila T et al (2006) Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 26:916–922

    Article  PubMed  CAS  Google Scholar 

  12. Konttinen L, Kankaanpaa E, Luosujarvi R et al (2006) Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25:882–884

    Article  PubMed  Google Scholar 

  13. Nordstrom DC, Konttinen L, Korpela M et al (2006) Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int26:741–748

    Article  PubMed  CAS  Google Scholar 

  14. Zochling J, Bohl-Bühler MHJ, Baraliakos X et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Clin Rheumatol 25:794–800

    Article  PubMed  Google Scholar 

  15. Breban M, Vignon E, Claudepierre P et al (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 41:1280–1285

    Article  PubMed  CAS  Google Scholar 

  16. Temekonidis TI, Alamanos Y, Nikas SN et al (2003) Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 62:1218–1220

    Article  PubMed  CAS  Google Scholar 

  17. Maksymowych WP, Jhangri GS, Lambert RG et al (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959–965

    PubMed  CAS  Google Scholar 

  18. Braun J, Baraliakos X, Brandt J et al (2005) Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 34:178–190

    Article  PubMed  CAS  Google Scholar 

  19. Mottonen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353:1568–1573

    Article  PubMed  CAS  Google Scholar 

  20. Wagner CL, Schantz A, Barnathan E et al (2003) Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol 112:37–53

    CAS  Google Scholar 

  21. Altan L, Bingol U, Karakoc Y et al (2001) Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30:255–259

    Article  PubMed  CAS  Google Scholar 

  22. Roychowdhury B, Bintley-Bagot S, Bulgen DY et al (2002) Is methotrexate effective in ankylosing spondylitis? Rheumatology 41:1330–1332

    Article  PubMed  CAS  Google Scholar 

  23. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M et al (2004) Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31:1568–1574

    PubMed  CAS  Google Scholar 

  24. Pham T, Landewe R, van der Linden S et al (2006) An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 65:1620–1625

    Article  PubMed  CAS  Google Scholar 

  25. Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42:2325–2329

    Article  PubMed  CAS  Google Scholar 

  26. Keystone EC (2003) Advances in targeted therapy: safety of biological agents. Ann Rheum Dis 62:ii34–ii36

    Article  PubMed  Google Scholar 

  27. Haraoui B, Keystone E (2006) Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 18:96–100

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The expert data processing and statistical assistance by Dr. Viljami Laine and secretarial assistance by Secretary Taina Käyhkö are greatly appreciated. This study has been supported by the Victoria Foundation, Finska Läkaresällskapet, the Perklen Foundation, the Juselius Foundation, the Center of Excellence of the Academy of Finland, and EVO projects. The ROB-FIN register has been financially supported by grants from Schering-Plough, Wyeth, Amgen, Abbott, and Biovitrum.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dan Nordström.

Additional information

On behalf of the ROB-FIN Study Group

Rights and permissions

Reprints and permissions

About this article

Cite this article

Konttinen, L., Tuompo, R., Uusitalo, T. et al. Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. Clin Rheumatol 26, 1693–1700 (2007). https://doi.org/10.1007/s10067-007-0574-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-007-0574-5

Keywords

Navigation